MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/92.5/0.1/20.12.24 | Real-time Bid/Ask 06:48:51 11/06/2024 pm IST | ||
| 0.14 EUR / 0.16 EUR | -12.28% |
|
| Current month | +34.65% | ||
| 1 month | +39.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 11/24/11 | 0.168 | -1.75% |
| 10/24/10 | 0.171 | +3.01% |
| 07/24/07 | 0.166 | -7.26% |
| 06/24/06 | 0.179 | +0.56% |
| 05/24/05 | 0.178 | +9.88% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 02:12 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB5CV6 |
| ISIN | DE000MB5CV61 |
| Date issued | 06/04/2023 |
| Strike | 92.5 $ |
| Maturity | 20/12/2024 (192 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.44 € |
|---|---|
| Lowest since issue | 0.013 € |
| Spread | 0.02 € |
| Spread % | 12.50% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
160.3
USD
Average target price
174.4
USD
Spread / Average Target
+8.77%
- Stock Market
- Warrants
- Warrant
